Category C—Although some reports have attempted to link trifluoperazine with congenital defects, most evidence suggests that the drug is safe for the mother and low risk for the embryo-fetus.
No reports describing the use of trifluoperazine during lactation have been located. The molecular weight (about 408 for the free base) is low enough that passage into milk should be expected. In 2001 the American Academy of Pediatrics classified trifluoperazine as a drug for which the effect on nursing infants is unknown but may be of concern.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic function, concomitant disease or other drug therapy.
No dosage adjustment necessary.
Use with caution in patients with hepatic impairment.